• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

    11/14/23 5:25:00 PM ET
    $ASH
    $MRK
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASH alert in real time by email

    WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India.

    As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annual Stockholders Meeting in January 2024. With the addition of Chattopadhyay, Ashland temporarily increases the size of the Board to 11 members until the next Annual Stockholders Meeting in January 2024.

    Chattopadhyay is a broadly experienced global executive who brings strong industry leadership in manufacturing, distribution, supply chain, and more. He has led complex operations that span 22 countries including cutting-edge manufacturing technology while successfully navigating the ever-changing, globally complex, and heavily regulated industry of biopharmaceuticals.

    "I am pleased to welcome Sanat as a new director to the Ashland Board," said Guillermo Novo, chair and chief executive officer, Ashland. "As we continue to execute our strategy and increase our focus and scale in pharmaceuticals, personal care and coatings, I am confident Sanat will provide important perspectives for our team. And once again, I want to thank Jay and Brendan for their dedicated service to the Board."

    To learn more, visit investor.ashland.com

    About Ashland 

    Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. 

    ™ Trademark, Ashland or its subsidiaries, registered in various countries.

    FOR FURTHER INFORMATION:

    Investor Relations:Media Relations:
    Seth A. MrozekCarolmarie C. Brown
    +1 (302) 594-5010+1 (302) 995-3158
    samrozek@ashland.comccbrown@ashland.com

    Attachment

    • Ashland_announces_new_board_member_20231114


    Primary Logo

    Get the next $ASH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASH
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    5/6/2026$125.00Neutral
    Citigroup
    Ashland Inc.
    $ASH
    5/6/2026$75.00Neutral → Buy
    Seaport Research Partners
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    Ashland Inc.
    $ASH
    12/15/2025$71.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $ASH
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

    At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectively LIPFENDRA is a novel macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA® (enlicitide) tablets 20 mg as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA is a novel macrocyclic peptide and is the first F

    7/16/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

    Late-breaker presentations will highlight investigational, once-weekly oral combinations of islatravir with lenacapavir (Phase 3 ISL/LEN) and with ulonivirine (Phase 2b ISL+ULO) in adults with virologically-suppressed HIV-1 Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV treatment and prevention will be presented at the 26th International AIDS Conference (AIDS 2026), taking place July 26-31, 2026, in Rio de Janeiro, Brazil. "Building on the momentum of the recent FDA approval of IDVYNSO, AIDS 2026 is an exciting moment to showcase the next chapter of Merck’s HIV pipeline – particularly our focus on

    7/15/26 7:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

    KEYTRUDA is the first and only PD-1 inhibitor to improve PFS compared to platinum doublet chemotherapy for these patients in a Phase 3 trial Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence more than six months after completing prior adjuvant therapy. KEYTRUDA is the first and only PD-1 inhibitor to show a st

    7/15/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Merck with a new price target

    Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $125.00

    5/6/26 7:35:08 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland upgraded by Seaport Research Partners with a new price target

    Seaport Research Partners upgraded Ashland from Neutral to Buy and set a new price target of $75.00

    5/6/26 7:31:43 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    SEC Filings

    View All

    SEC Form 11-K filed by Merck & Company Inc.

    11-K - Merck & Co., Inc. (0000310158) (Filer)

    6/24/26 3:12:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Merck & Company Inc.

    11-K - Merck & Co., Inc. (0000310158) (Filer)

    6/24/26 3:08:47 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Merck & Company Inc.

    11-K - Merck & Co., Inc. (0000310158) (Filer)

    6/24/26 3:05:10 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Bishop Steven D

    4 - ASHLAND INC. (0001674862) (Issuer)

    7/1/26 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 4 filed by Director Chattopadhyay Sanat

    4 - ASHLAND INC. (0001674862) (Issuer)

    7/1/26 4:30:06 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 4 filed by Director Seidman Christine E

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    7/1/26 8:47:10 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    ITT Announces Appointment of Bertrand Loy and Kevin Wheeler to Board of Directors

    June 29, 2026-- ITT Inc. (NYSE: ITT) today announced the election of Bertrand Loy and Kevin Wheeler to its Board of Directors. "We are delighted to appoint to the ITT Board two highly accomplished, results-driven leaders," said ITT Chair of the Board Nazzic S. Keene. "Their appointments reflect our disciplined approach to board refreshment and our focus on adding directors with capabilities and skillsets aligned with the strategic direction and business goals of ITT." "Bertrand brings a powerful combination of public company CEO experience, global manufacturing and supply chain leadership, and a strong record of scaling technology-driven industrial businesses driven by both organic and

    6/29/26 4:30:00 PM ET
    $ITT
    $ENTG
    $ASH
    Fluid Controls
    Industrials
    Plastic Products
    Specialty Chemicals

    Ashland Board appoints Bertrand Loy as new director

    WILMINGTON, Del., May 18, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is announcing the appointment of Bertrand Loy to its board of directors, effective May 15, 2026. Loy currently serves as a director and the executive chair of Entegris Inc. (NASDAQ:ENTG), a leading supplier of advanced materials and process solutions for the semiconductor and high-technology industries and previously served as Entegris' president and chief executive officer. He will serve on the board's audit and governance and nominating committees, also effective as of May 15, 2026. With the addition of Loy and in anticipation of potential director retirements under the board's retirement and resignation policy,

    5/18/26 7:00:00 AM ET
    $ASH
    $ENTG
    Specialty Chemicals
    Consumer Discretionary
    Plastic Products
    Industrials

    Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called "Bad" Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

    The Yankees, Red Sox, Phillies, Braves, Astros, Cardinals, Giants, Padres, and Angels are joining Merck to help educate fans about high bad cholesterol and how it may increase the risk of heart attack or stroke Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called "bad" cholesterol, number and the potential increased risk of heart attack or stroke. Playing with Heart connects Merck's commitment to

    4/28/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Financials

    Live finance-specific insights

    View All

    Ashland sets date for third-quarter fiscal 2026 earnings release and conference call webcast

    WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its third-quarter fiscal 2026 earnings release at approximately 5 p.m. ET on Tuesday, July 28, 2026. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, July 29.  Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, senior vice president, and chief financ

    7/14/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Aug. 4. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fre

    7/1/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ancora Releases Presentation Highlighting the Opportunity for a Value-Maximizing, Competitive Sale Process at Ashland Inc.

    Believes Ashland's High-Margin, Strategically Scarce Assets Are Being Undervalued by the Public Markets in the Face of Near-Term Growth and Execution Issues Urges Ashland's Board to Conduct a Full Review of Strategic Alternatives, Including Evaluating Sale Options Following Apparent Interest from Standard Industries as Well as Other Strategic and Private Equity Buyers Releases Presentation Outlining How a Sale Could Yield ~$76 Per Share or More, Representing a More Than 33% Premium and Likely the Best Risk-Adjusted Path Forward Ancora Holdings Group, LLC (collectively with its affiliates, "Ancora") today released a presentation (available here) detailing what it believes is a near-ter

    6/9/26 4:05:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ashland Inc.

    SC 13G - ASHLAND INC. (0001674862) (Subject)

    11/12/24 11:54:03 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Ashland Inc.

    SC 13G/A - ASHLAND INC. (0001674862) (Subject)

    7/10/24 1:14:41 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

    SC 13D/A - ASHLAND INC. (0001674862) (Subject)

    4/25/24 4:15:12 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary